IRD: Opus Genetics cites positive Cohort 1 low-dose Phase 1/2 data
Opus Genetics reported positive low-dose Cohort 1 data from Phase 1/2 trial of OPGx-BEST1 and a successful FDA Type C meeting.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.